DBV Technologies S.A. (FRA:DBV)
2.210
0.00 (0.00%)
At close: Dec 5, 2025
DBV Technologies Revenue
DBV Technologies had revenue of $2.77M USD in the quarter ending September 30, 2025, with 158.77% growth. This brings the company's revenue in the last twelve months to $5.50M, down -56.04% year-over-year. In the year 2024, DBV Technologies had annual revenue of $4.15M, down -73.61%.
Revenue (ttm)
$5.50M
Revenue Growth
-56.04%
P/S Ratio
86.97
Revenue / Employee
$50.02K
Employees
110
Market Cap
407.85M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
DBV Technologies News
- 2 days ago - DBVT: Guggenheim Initiates Coverage with 'Buy' Rating and $35 PT | DBVT Stock News - GuruFocus
- 23 days ago - DBVT Completes Key Phase 3 Trial for Peanut Allergy Treatment - GuruFocus
- 24 days ago - DBV Technologies On Track To Report Data From VITESSE Phase 3 Trial Of VIASKIN Peanut Patch In Q4 - Nasdaq
- 24 days ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN Peanut Patch in Peanut Allergic Children Aged 4-7 Years - Wallstreet:Online
- 24 days ago - DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - GlobeNewsWire
- 4 weeks ago - DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 4 weeks ago - DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - GlobeNewsWire
- 5 weeks ago - DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - GlobeNewsWire